Leveraging experience, knowledge, and expertise from almost three decades of viral vector development and manufacturing, we offer a scalable, reproducible, and efficient development solution to de-risk lentivirus production.
Our VirusExpress® platform for lentiviral vectors provides an accelerated path to clinical and commercial GMP manufacturing, through our robust and streamlined approach with optimized upstream and downstream workflows and comprehensive analytics.
With more than 25 years of experience working with viral vectors, our VirusExpress® platform is designed to accelerate development and de-risk manufacturing of lentiviral vectors through our proven, scalable, and reproducible workflows.
Working with us you gain an efficient and knowledgeable approach, and confidence in the quality of the clinical and commercial manufacturing of your lentiviral vector.
Our team of development and manufacturing experts have successfully compress project timelines and seamlessly scaled-up lentiviral-based gene therapy programs through IND-submission and into clinical trials.
By incorporating optimized upstream and downstream unit operations, along with an extensive analytics portfolio, cell and gene therapy innovators benefit from a de-risked, reproducible, and efficient development approach to seamlessly and robustly scale-up to clinical and commercial manufacturing, while improving overall yield and quality and compressing timelines from project start to GMP manufacturing in less than 12 months.
In this webinar, our innovation scientists explore how they optimized our VirusExpress® platform for lentiviral vectors to maximize titer, while providing a streamlined platform to accelerate development timelines to clinical trials.
Learn how our Manufacturability Assessment can help identify and address development and manufacturing challenges when bringing new therapies to market.
Watch the video and read the poster to learn how we optimized our VirusExpress® platform for lentiviral vectors to maximize titers, enrich recovery, and reduce time to GMP manufacturing.
To continue reading please sign in or create an account.Don't Have An Account?